<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252135</url>
  </required_header>
  <id_info>
    <org_study_id>Q2948g</org_study_id>
    <nct_id>NCT00252135</nct_id>
  </id_info>
  <brief_title>A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma</brief_title>
  <official_title>An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study is a multicenter, prospective, observational cohort study of ~5000 Xolair-treated&#xD;
      and ~2500 non-Xolair-treated patients with moderate to severe persistent asthma and a&#xD;
      positive skin test or in vitro reactivity to an aeroallergen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2004</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">8023</enrollment>
  <condition>Asthma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from a variety of practice settings, including managed care&#xD;
        organizations, community physicians, and academic centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent document (in the case of a minor, consent must be given by the&#xD;
             child's parent or legally authorized representative)&#xD;
&#xD;
          -  â‰¥12 years of age&#xD;
&#xD;
          -  Physician diagnosis of moderate to severe persistent asthma&#xD;
&#xD;
          -  Evidence or history of positive skin test or in vitro reactivity to an aeroallergen&#xD;
&#xD;
          -  Willingness to participate fully for the duration of the study (5 years)&#xD;
&#xD;
          -  For patients in the Xolair-treated cohort, have received at least one dose of Xolair&#xD;
             therapy at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to Xolair therapy (e.g., patients who experienced a severe&#xD;
             hypersensitivity reaction to Xolair)&#xD;
&#xD;
          -  Acute asthma exacerbation within the previous 2 weeks of screening requiring any of&#xD;
             the following: initiation of systemic corticosteroids, increased doses of systemic&#xD;
             corticosteroids from baseline, doubling of inhaled corticosteroids, emergency room&#xD;
             visit, or hospitalization&#xD;
&#xD;
          -  Acute flare of significant systemic disease (e.g., infection, hematologic, renal,&#xD;
             hepatic, cardiovascular diseases, or gastrointestinal diseases), or a recent&#xD;
             hospitalization because of their disease within the previous 2 months&#xD;
&#xD;
          -  Use of an experimental drug within 30 days prior to study screening&#xD;
&#xD;
          -  Diagnosis of cystic fibrosis&#xD;
&#xD;
          -  For patients in the non-Xolair-treated cohort, any prior treatment with Xolair&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Wong, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2005</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

